ロード中...
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa
We evaluated Eastern Cooperative Group phase II and III trials E2696 and E1694 to assess the incidence and prognostic significance of autoimmunity induced by adjuvant high-dose interferon-α2b (HDI). In E2696, patients with resectable high-risk melanoma were randomized to receive vaccination with GM2...
保存先:
| 出版年: | Melanoma Res |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4308690/ https://ncbi.nlm.nih.gov/pubmed/24509407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000050 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|